Wedbush downgraded Longboard Pharmaceuticals to Neutral from Outperform with a $60 price target after the company agreed to be acquired by Ludbeck for $2.6B or $60 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals deal comes earlier than expected, says Truist
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley
- Longboard Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
- Morning Movers: Longboard Pharmaceuticals surges following deal to be acquired
- Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B